Despite being the seventh adalimumab biosimilar approved in the United States, there are none on the market yet. The FDA has approved a seventh adalimumab biosimilar, Yusimry, which is developed by ...
Today, Coherus BioSciences, Inc. announced that the FDA approved YUSIMRY (adalimumab-aqvh), a biosimilar of AbbVie’s HUMIRA product. YUSIMRY is indicated for plaque psoriasis, psoriatic arthritis, ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the seventh biosimilar to adalimumab, adalimumab-aqvh, for all eligible indications of the ...
Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...
DALLAS, Texas and REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Mark Cuban Cost Plus Drug Company, PBC (“Cost Plus Drugs” or “Mark Cuban Cost Plus Drug Company”) and Coherus BioSciences, Inc ...
REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS) (“Coherus”, Nasdaq: CHRS) and specialty pharmacy Superior Biologics, Inc. (“Superior Biologics”) today ...
REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023* with a list price of ...
REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback